To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.
Sponsor
Pfizer (Industry)
Overall Status
Completed
CT.gov ID
NCT00150436
Collaborator
(none)
276
40.9
Study Details
Study Description
Brief Summary
To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Study Design
Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open-Label Extension Safety and Efficacy Study of Pregabalin in Patients With Postherpetic Neuralgia
Study Start Date
:
Feb 1, 2002
Study Completion Date
:
Jul 1, 2005
Outcome Measures
Primary Outcome Measures
- Safety Efficacy []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Must have met the inclusion criteria for preceding double-blind BID study in postherpetic neuralgia
-
Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.
Exclusion Criteria:
- Patients cannot participate if they experienced a serious adverse event during preceding double-blind BID study which was determined to be related to the study medication.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00150436
Other Study ID Numbers:
- 1008-198
First Posted:
Sep 8, 2005
Last Update Posted:
Dec 22, 2006
Last Verified:
Dec 1, 2006